Download - Generic Drugs Review
8/11/2019 Generic Drugs Review
http://slidepdf.com/reader/full/generic-drugs-review 1/36
Generic Drug Review
Hanan KakishMedical Research Scientist, M.Sc. Pharm.
Middle East and North Africa Post
Office of International Programs
U.S. Food and Drug Administration
1
8/11/2019 Generic Drugs Review
http://slidepdf.com/reader/full/generic-drugs-review 2/36
Disclaimer
This presentation constitutes an informal communication
that represents the best judgment of the speaker at this
time but does not constitute an advisory opinion, does not
necessarily represent the formal position of U.S. FDA,and does not bind or otherwise obligate or commit the
U.S. FDA to the views expressed
2
8/11/2019 Generic Drugs Review
http://slidepdf.com/reader/full/generic-drugs-review 3/36
FDA Product RegulationFDA is organized around the products it regulates.
• CDER: Center for Drug Evaluation and Research (also
responsible for therapeutic proteins/antibodies)
• CBER: Center for Biologics Evaluation and Research
including vaccine and blood products• CDRH: Center for Devices and Radiological Health
• CVM: Center for Veterinary Medicine
• CFSAN: Center for Food Safety and Applied Nutrition
• CTP: Center for Tobacco Products
In addition:
• ORA: Office of Regulatory Affairs (The field)
•
NCTR: National Center for Toxicological Research 3
8/11/2019 Generic Drugs Review
http://slidepdf.com/reader/full/generic-drugs-review 4/36
CDER Mission: to ensure that SAFE and EFFECTIVE prescription, non-prescription, and generic drugs are available to
the American public. CDER evaluates applications through
review teams:
• To assure that the data submitted are adequate and scientifically
sound
• Assess the submitted data, make recommendations, and
document the decision rationale
• Provide feedback to sponsor’s proposal for the next stage of
development and approval
4
8/11/2019 Generic Drugs Review
http://slidepdf.com/reader/full/generic-drugs-review 5/36
CDER Offices
Most relevant offices to generic review are:1. Office of Compliance is the lead within CDER for the
management of establishment evaluation and the inspection process for supplemental applications to approved NDAs/ANDAs.
• Drug Manufacturing Inspections Compliance PolicyGuidance Manual (2/1/2002, 7356.002)
• Pre-Approval Inspections Compliance Policy GuidanceManual (5/10/2010, 7346.832)
• Post-Approval Audit Inspections Compliance Policy
Guidance Manual (7346.832)
2. Office of Pharmaceutical Science (OPS) is the lead withinCDER for the review of the Product Quality informationsubmitted in supplemental applications to approved
NDAs/ANDAs. 5
8/11/2019 Generic Drugs Review
http://slidepdf.com/reader/full/generic-drugs-review 6/36
FDA Marketing Authorization Applications
• Investigational New Drug (IND) Application
Allows initiation of clinical studies in humans
Allows inter-state shipping of drug candidate to clinical trial
sites
• New Drug Application (NDA)/Biologics License
Application (BLA)
Submission of information needed for marketing approval
• Abbreviated New Drug Application (ANDA)
Application for approval of a generic drug.
Reviewed by the Office of Generic Drugs (OGD)
6
8/11/2019 Generic Drugs Review
http://slidepdf.com/reader/full/generic-drugs-review 7/36
Generic Drugs• A generic drug is therapeutically equivalent to the brand name
drug.
• Therapeutic Equivalence “have the same clinical effect and
safety profile when administered to patients under the conditions
specified in the labeling”
• FDA Practice
Pharmaceutical Equivalence + Bioequivalence = Therapeutic Equivalence
• Generic drug products provide the public with safe, effective,and low cost alternatives to innovator drugs.
• ANDAs are generally not required to include preclinical and
clinical data to establish safety and effectiveness. (i.e.,it
performs in the same manner as the innovator drug). 7
8/11/2019 Generic Drugs Review
http://slidepdf.com/reader/full/generic-drugs-review 8/36
8
Generic Drug Availability in the US
With generics now covering ~80% of total prescriptions filled
with a tremendous cost savings to the US market, it is important
that drug product quality is assured.
In August 2012, the Generic
Pharmaceutical Association
released an independently
conducted analysis showing that
the savings to consumers and the
U.S. health care system from the
use of generic prescription
drugs has risen to a current rate of
$1 billion every other day —
totaling $193 billion in 2011 and
more than $1 trillion over the last10 years (2002-2011).
2011 spending
increase $5.6 BN
8/11/2019 Generic Drugs Review
http://slidepdf.com/reader/full/generic-drugs-review 9/36
Generic Drug
The following regulations apply to the ANDA process:• Applications for FDA Approval to Market a New Drug or an
Antibiotic Drug
• Bioavailability and Bioequivalence Requirements
• Bioequivalence Study Retention Samples
• Bioavailability and Bioequivalence Requirements; Abbreviated
Applications; Final Rule
A complete list of drug guidance documents, including ones forANDA approval is available at:
http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInforma
tion/Guidances/default.htm
9
8/11/2019 Generic Drugs Review
http://slidepdf.com/reader/full/generic-drugs-review 10/36
Generic Drug Requirements
For a generic drug to be approved, it must, when compared to
the reference drug, have:
1. Same active ingredient(s)
2. Same dosage form
3. Same route of administration
4. Same labeled strength
5. Same conditions of use
6. Meet compendial or other applicable standards of strength,
quality, purity, and identity
10
8/11/2019 Generic Drugs Review
http://slidepdf.com/reader/full/generic-drugs-review 11/36
Generic Drug Requirements - Cont.
1. Fully documented chemistry, manufacturing steps, and
quality control measures. Detailed manufacturing process,
step-by-step
2. The raw materials and the finished product must meet USPspecifications (if applicable)
3. The generic drug must maintain stability as labeled and
continue to monitor drug’s stability
4. The generic drug’s labeling must be basically the same as that
of the approved brand-name drug
11
8/11/2019 Generic Drugs Review
http://slidepdf.com/reader/full/generic-drugs-review 12/36
Generic Drug Requirements - Cont.
5. The drug company must show the generic drug is“bioequivalent” to the brand-name drug.
6. The drug company must:
• comply with federal regulations for current good
manufacturing practices
• give a full identification of the facilities it uses to
manufacture, process, test, package, label, and control the
drug
7. Inspection at the proposed manufacturing site ensures that the
firm:
• is capable of meeting commitments of the application
• can manufacture the product consistently12
8/11/2019 Generic Drugs Review
http://slidepdf.com/reader/full/generic-drugs-review 13/36
NDA vs. ANDA Review Process
Brand Name Drug Generic DrugNDA Requirements ANDA Requirements
1. Chemistry /Micro 1. Chemistry/Micro
2. Manufacturing 2. Manufacturing
3. Controls 3. Controls4. Labeling 4. Labeling
5. Testing 5. Testing
6. Animal Studies
7. Clinical Studies 6. Bioequivalence8. Bioavailability
Number of annual generic drug approvals > new drug
approvals
CMC
13
8/11/2019 Generic Drugs Review
http://slidepdf.com/reader/full/generic-drugs-review 14/36
Generic Drugs: Assurance of Quality• First 5 steps (Chemistry, manufacture, control, label,
testing) of review process are identical to NDA process.
• Bioequivalence is reviewed by OGD, in case of complicated
products might be reviewed by other offices.
• FDA has extensive experience with the innovator drug
product.
• Scientific literature published about the innovator drug
• Product is known to be safe.
14
8/11/2019 Generic Drugs Review
http://slidepdf.com/reader/full/generic-drugs-review 15/36
Generic Drug
Review Process
Bioequivalence ReviewLabeling ReviewChemistry & MicroReview
Request for PlantInspection
APPLICANT
ANDA
Acceptable
& Complete
Application Review
NChem/Micro
OK?
Labeling
OK?
Bioequivalence
OK?
Pre-Approval
Inspection Results
OK?
Complete Response
Letter
Approval Withheld
until Results
SatisfactoryAPPROVED
ANDA
NNN
N
Y Y Y
Y
Y
Refuse to Receive
Letter
http://www.fda.gov/cder/ob/15
8/11/2019 Generic Drugs Review
http://slidepdf.com/reader/full/generic-drugs-review 16/36
FDA RequirementsBrand Name
Drug
Generic
Drug
FDA evaluates the manufacturer's adherence to good
manufacturing practices before the drug is marketed.
FDA reviews the active and inactive ingredients used in the
formulation before the drug is marketed.
FDA reviews the actual drug product.
FDA reviews the drug's labeling.
Manufacturer must seek FDA approval before making major
manufacturing changes or reformulating the drug.
For reformulations of a brand-name drug or generic versions
of a drug, FDA reviews data showing the drug is bioequivalent
to the one used in the original safety and efficacy testing.
Manufacturer must report adverse reactions and serious
adverse health effects to the FDA.
FDA periodically inspects manufacturing plants.
FDA monitors drug quality after approval. 16
8/11/2019 Generic Drugs Review
http://slidepdf.com/reader/full/generic-drugs-review 17/36
• Components and Composition: make sure that the formulation isstable and in compliance with FDA regulations and standards.
• Manufacturing and Controls
• Batch Formulation and Records
• Description of Facilities (for sterilized or aseptic processes)
• Specifications and Tests: make sure that impurities are within FDA
acceptable limits and the tests are appropriate for that product.
• Packaging: to make sure it assures the stability of the product (withthe proper product design, manufacturing quality control and
storage conditions)
• Stability: to assure that the shelf life of the product is appropriate.
CMC Review
17
8/11/2019 Generic Drugs Review
http://slidepdf.com/reader/full/generic-drugs-review 18/36
• Office of New Drug Quality Assessment has adopted ICH Q1A.
• OGD has adopted ICH Q1A for Drug Substances but does not
have a formal published stability guidance for drug products and
generally relies on same ICH Guidance documents which CDERrelies on for brand drugs.
• A draft guidance is posted on FDA web site on September 2012
(will become official by January 2014). Available at:http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInform
ation/Guidances/UCM320590.pdf
So, industry will have to revise their scheduling to accommodatenew filing requirements.
Current Status & Emerging Stability Expectations at OGD
18
8/11/2019 Generic Drugs Review
http://slidepdf.com/reader/full/generic-drugs-review 19/36
Current/New Expected ANDA Stability Data Submission Requirements
19
Requirements Current Draft Guidance
Accelerated
Stability Data
3 months at 40°C ± 2°C/75%
RH ± 5% RH
6 months at 40°C ± 2°C/75% RH ± 5% RH
(at time of submission)
Intermediate _____________6 months at 30°C ± 2°C/65% RH ± 5%
RH, if 6 months accelerated fails
Long Term
Stability Data
(at time of
submission)
3 months long term stability
data at 25°C ± 2°C/60% RH ±
5% RH
6 months at 25°C ± 2°C/60% RH ± 5%
RH, or
6 months at 30°C ± 2°C/65% RH ± 5% RH
Batch
Requirements
One lot of drug product
which is at least 10% of theintended market batch size or
100,000 dosage units,
whichever is greater (size of
the exhibit lot may vary upon
consultation with the Office)
At least 3 primary batches of drug product
(2 of the 3 batches should be at least pilot scale)
•Same formulation, manufacturing process
& specifications as those for market.
•Same container/closure system as proposed
for market.
•Different lots of API where possible.
8/11/2019 Generic Drugs Review
http://slidepdf.com/reader/full/generic-drugs-review 21/36
Labeling Review• “Same” as brand name labeling
• May delete portions of labeling protected by patents or
exclusivity
• May differ in excipients, PK data, and how supplied
BE Review: Review BE and waiver requests.
To assure that the two products perform in an equivalent manner.
Showing that the active ingredient is absorbed at the same rateand extent as the reference product allows the generic to rely on
the findings of safety and efficacy of that innovator product.
Generic Drug Review
21
8/11/2019 Generic Drugs Review
http://slidepdf.com/reader/full/generic-drugs-review 22/36
Clinical Review
• Reviews BE studies with clinical endpoints
• Evaluates safety issues (inactive ingredients, adverse
events, etc.)• Assesses clinical issues in ANDAs (effect of different
vehicles, inactive ingredients)
• Assesses equivalence challenges
Generic Drug Review
22
8/11/2019 Generic Drugs Review
http://slidepdf.com/reader/full/generic-drugs-review 23/36
Manufacturing Compliance Programs
• Purpose - To assure quality of marketed drug products
• Product Testing
• Surveillance
Manufacturing/Testing Site Inspections (Establishment
Evaluation Requests [EERs])
Assess firm’s compliance with good manufacturing/
laboratory processes
Generic Drug Review
23
8/11/2019 Generic Drugs Review
http://slidepdf.com/reader/full/generic-drugs-review 24/36
QbD is a systematic approach for designing and developing
formulations and for manufacturing processes to ensure
predefined product quality.
Design of experiments and risk assessment are tools to
facilitate the implementation of QbD
Implementing Quality by Design
(QbD)
24
8/11/2019 Generic Drugs Review
http://slidepdf.com/reader/full/generic-drugs-review 25/36
QbR is a general framework that provides a science and risk-
based assessment of drug product quality.
• Contains 37 important scientific and regulatory review questions.
• ANDA applicants answer the questions.
• Chemistry reviewers evaluate the responses to the questions
along with the body of data.
The questions incorporate QbD principles and require the applicant
to demonstrate their level of process and product understanding.
Question-based Review (QbR)
25
8/11/2019 Generic Drugs Review
http://slidepdf.com/reader/full/generic-drugs-review 26/36
What are the Advantages of QbR?
26
8/11/2019 Generic Drugs Review
http://slidepdf.com/reader/full/generic-drugs-review 27/36
• In January, 2012, OGD began to include a recommendation ineach letter to an applicant strongly recommending that QbD
principles be used in the development of future submissions.
• OGD will continue to work with the industry to implement
QbD for generic drugs as quickly and smoothly as possible.
• OGD has developed hypothetical examples (not templates) for
Immediate and Modified Release drug products to demonstrate
the process of using the revised QbR/QbD format. Theseexamples can be found online at FDA's Generic Drugs:
Information for Industry webpage at:http://www.fda.gov/Drugs/DevelopmentApprovalProcess/HowDrugsareDev
elopedandApproved/ApprovalApplications/AbbreviatedNewDrugApplicatio
nANDAGenerics/ucm142112.htm
QbD at the Office of Generic Drugs
27
8/11/2019 Generic Drugs Review
http://slidepdf.com/reader/full/generic-drugs-review 28/36
ANDA FormatCommon Technical Document (CTD)
• Module 1: Administrative information (region specific) and
labeling
• Module 2: Summaries of the information that is provided (in
full) in the remaining modules & includes a Quality-related
subsection called the Quality Overall Summary (QOS)
• Module 3: Quality
• Module 4: Preclinical
• Module 5: ClinicalOGD’s ANDA Checklist contains detailed information regardingwhere documents are to be placed. ANDA Checklist forCompleteness and Acceptability is available on the FDA website
eCTD format is preferred. 28
8/11/2019 Generic Drugs Review
http://slidepdf.com/reader/full/generic-drugs-review 29/36
eCTD• eCTD, accepted since 2003, became FDA’s standard in 2008.
Receive 400-600 e-submissions daily
• FDA has published draft eCTD guidance in Jan 2013 and
the applications subject to agency's actions (ANDA, NDA,
BLA) are required to be in eCTD format in two years once theguidance is finalize and in three years for certain IND.
• DMF is highly encouraged to be in eCTD format.
• All eCTD submissions are validated for compliance with FDAstandards
• Validations errors are assigned a severity level: High, Medium,
Low, & Ignore. (High errors cause rejection of submission)29
8/11/2019 Generic Drugs Review
http://slidepdf.com/reader/full/generic-drugs-review 30/36
The e-Submission Process
Sponsor obtains pre-assigned applicationnumber from FDA
Sponsor sends submission
Document Room (EDR) and automated processes validate and load the submission
Review teams are notified
30
8/11/2019 Generic Drugs Review
http://slidepdf.com/reader/full/generic-drugs-review 31/36
The e-Submission Process
e-Submissions are sent by:
• Electronic Secure Gateway
• USB Portable Hard Drive
• CD-ROM/DVD
(Tape is no longer an option; phased out by 12/31/2012)
31
8/11/2019 Generic Drugs Review
http://slidepdf.com/reader/full/generic-drugs-review 32/36
What Gets Rejected (eCTD)?
How Many are Rejected?
~1% of submissions are rejected
(current averages are 10,000 submissions per month, 100
rejected)
Reasons for Rejection:
• Invalid submission number or type
• Single file submissions• High-level validation errors
• Duplicate submissions
32
8/11/2019 Generic Drugs Review
http://slidepdf.com/reader/full/generic-drugs-review 33/36
For Questions
Contact:
1. MENA Post at:
2. Office of Generic Drugs at
33
8/11/2019 Generic Drugs Review
http://slidepdf.com/reader/full/generic-drugs-review 34/36
References
1. The Office of Generic Drugs home pagehttp://www.fda.gov/Drugs/DevelopmentApprovalProcess/HowDrug
sareDevelopedandApproved/ApprovalApplications/AbbreviatedNe
wDrugApplicationANDAGenerics/ucm142112.htm
2. Abbreviated New Drug Application (ANDA): Generics
http://www.fda.gov/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/ApprovalApplications/AbbreviatedNew
DrugApplicationANDAGenerics/default.htm
3. ANDA Filling Checklist
http://www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess
/HowDrugsareDevelopedandApproved/ApprovalApplications/Abbre
viatedNewDrugApplicationANDAGenerics/UCM151259.pdf
4. CDER’s Training and Continuing Education Page
http://www.fda.gov/Training/ForHealthProfessionals/default.htm
34
8/11/2019 Generic Drugs Review
http://slidepdf.com/reader/full/generic-drugs-review 35/36
References
5. CDER’s Consumer Education page www.fda.gov/usemedicinesafely
6. FDA eCTD web page:
http://www.fda.gov/Drugs/DevelopmentApprovalProcess/FormsSub
missionRequirements/ElectronicSubmissions/ucm153574.htm
7. Guidance Documents
http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformati
on/Guidances/ucm121568.htm
35